% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • nhanduyvo nhanduyvo May 24, 2013 12:43 AM Flag

    Recardo - Celldex Therapeutics, Inc. to Discuss Topline Results of CDX-011 Conference Call

    CLDX had a conference call today (5/23/13) at 4:30 pm to discuss the topline results of CDX-011.
    It did not present anything new other than to confirm the study result.

    Based on your expertise on medicine field, do you think CLDX can successfully get CDX-011 to market?

    Thanks a lot for your insights and time.

    Best regards,

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Nhan,

      It's hard to predict whether any drug will eventually be brought to market at this stage of development. The data presented was nothing new, but once again pointed to the rationale supporting CLDX 's continuing its development toward a registration pathway..........within a select patient group in the general breast cancer patient population ( see below ).

      Based on this early data it seems fair to assign this product ( my personal speculation only ) a 50 / 50 chance or somewhat better that it may reach initial marketing in the setting of triple negative breast cancer with high GPNMB expression.

      Conceivably, the bar or threshold for an approval in this patient population would be lowered to begin with as present therapies are not that effective and there is a distinct clinically unmet need.

      Best of luck,


50.83-0.77(-1.49%)Oct 21 4:00 PMEDT